Drug intelligence / Profile preview

PT-630

Development stage: Discontinued
Lead developer: Biodexa Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

PT-630 is a small molecule inhibitor of dipeptidyl peptidase IV (DPP-4) and fibroblast activation protein (FAP). Developed by Point Therapeutics (later acquired by Midatech Pharma US), it was primarily investigated for the treatment of type 2 diabetes. The compound is a boronic acid derivative, specifically Glu-boroPro, which functions by inhibiting prolyl peptidases. These enzymes play significant roles in glucose metabolism and the regulation of the tumor microenvironment. PT-630's development was discontinued during the preclinical stage and did not advance to clinical trials.

Other names: Glu-boroProGlutamyl-boroproline

Targets

FAP (Fibroblast activation protein alpha)DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on PT-630.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PT-630.

Explore the full profile